首页> 美国卫生研究院文献>Molecular Oncology >Multi‐level gene expression signatures but not binary outperform Ki67 for the long term prognostication of breast cancer patients
【2h】

Multi‐level gene expression signatures but not binary outperform Ki67 for the long term prognostication of breast cancer patients

机译:在乳腺癌患者的长期预后方面多级基因表达特征而不是二进制特征优于Ki67

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proliferation‐related gene signatures have been proposed to aid breast cancer management by providing reproducible prognostic and predictive information on a patient‐by‐patient basis. It is unclear however, whether a less demanding assessment of cell division rate (as determined in clinical setting by expression of Ki67) can function in place of gene profiling.We investigated agreement between literature‐, distribution‐based, as well as signature‐derived values for Ki67, relative to the genomic grade index (GGI), 70‐gene signature, p53 signature, recurrence score (RS), and the molecular subtype models of Sorlie, Hu, and Parker in representative sets of 253 and 159 breast cancers with a median follow‐up of 13 and 14.5 years, respectively. The relevance for breast cancer specific survival was also addressed in uni‐ and bivariate Cox models.Taking both cohorts into account, our broad approach identified ROC optimized Ki67 cutoffs in the range of 8–28%. With optimum signature‐reproducing cutoffs, similarity in classification of individual tumors was higher for binary signatures (72–85%), than multi‐level signatures (67–73%). Consistent with strong agreement, no prognostic superiority was noted for either Ki67 or the binary GGI, 70‐gene and p53 signatures in the Uppsala dataset by bivariate analyses. In contrast, Ki67‐independent prognostic capacity could be demonstrated for RS and molecular subtypes according to Sorlie, Hu and Parker in both datasets.Our results show that the added prognostic value of binary proliferation‐related gene signatures is limited for Ki67‐assessed breast cancers. More complex, multi‐level descriptions have a greater potential in short‐ and long‐term prognostication for biologically relevant breast cancer subgroups.
机译:已经提出了与增殖有关的基因标记,通过在每个患者的基础上提供可再现的预后和预测信息来帮助乳腺癌的治疗。然而,目前尚不清楚,对细胞分裂率的较低要求(在临床环境中通过Ki67的表达确定)是否可以代替基因谱分析。我们研究了基于文献,基于分布以及基于签名的协议之间的一致性相对于基因组等级指数(GGI),70基因标记,p53标记,复发评分(RS)以及Sorlie,Hu和Parker分子亚型模型在253例和159例代表性乳腺癌中的Ki67值中位随访分别为13年和14.5年。在单变量和双变量Cox模型中也解决了与乳腺癌特异性生存的相关性。考虑到这两个队列,我们​​广泛的研究方法确定了ROC优化的Ki67临界值在8%至28%的范围内。如果具有最佳的特征复制截止值,则二元特征(72-85%)的个体肿瘤分类相似度要高于多层特征(67-73%)。与一致意见一致,通过双变量分析,在Uppsala数据集中,Ki67或二进制GGI,70基因和p53签名均未显示出预后优越性。相比之下,根据两个数据集中Sorlie,Hu和Parker的研究,可以证明RS和分子亚型的Ki67独立预后能力。我们的结果表明,与Ki67评估的乳腺癌相关的二元增殖相关基因标志的附加预后价值有限。对于生物学相关的乳腺癌亚组,更复杂的多层次描述在短期和长期预后中具有更大的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号